The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study

dc.contributor.authorEvangelista, Karine Cavalcanti Maurício Sena
dc.contributor.authorPedrosa, Lucia Fatima Campos
dc.contributor.authorPaiva, Maria Sanali Moura Oliveira
dc.contributor.authorDias, Paula Cristina Silveira
dc.contributor.authorFerreira, Diana Quitéria Cabral
dc.contributor.authorCozzolino, Sílvia Maria Franciscato
dc.contributor.authorFaulin, Tanize Espírito Santo
dc.contributor.authorAbdalla, Dulcinéia Saes Parra
dc.date.accessioned2024-08-26T21:27:57Z
dc.date.available2024-08-26T21:27:57Z
dc.date.issued2015-03
dc.description.resumoObjective: Statins treatment may modify the levels of zinc and selenium, minerals that can improve vascular function and reduce oxidative damage and inflammation in atherosclerotic patients. This study aimed to evaluate the effects of rosuvastatin, alone or associated with zinc and selenium supplementation, on lipid profile, antioxidant enzymes and mineral status in coronary artery disease patients. Material and Methods A double-blind randomized clinical trial was performed in which patients (n = 76) were treated with 10 mg rosuvastatin over 4 months associated or not with zinc (30 mg/d) and selenium (150 μg/d) supplementation. The following parameters were analyzed before and after the intervention: anthropometric measurements, lipid profile, high sensitivity C-reactive protein (hs-CRP), electronegative low density lipoprotein (LDL(-)) concentrations, activities of glutathione peroxidase (GPx), superoxide dismutase (SOD), zinc and selenium concentrations in blood plasma and erythocytes. Significance was determined using an α of 5% (twotailed). Results We found that rosuvastatin therapy was efficient in reducing total cholesterol, LDL-cholesterol, non-HDL cholesterol, triglycerides, and hs-CRP independently of mineral supplementation. Neither treatment was associated with significant changes in LDL(-). Similarly, the antioxidant enzymes GPx and SOD activity were unchanged by treatments. Neither treatment was associated with significant differences in concentrations of zinc or selenium in blood plasma and erythocytes of studied groups. Conclusion Rosuvastatin treatment did not affect zinc and selenium levels in coronary artery disease patients. The zinc and selenium supplementation at doses used in this study did not change lipid profile or SOD and GPx activity in patients receiving rosuvastatin. Further studies should be focused on testing alternative doses and supplements in different populations to contribute for a consensus on the ideal choice of antioxidants to be used as possible complementary therapies in atherosclerotic patientspt_BR
dc.identifier.citationEVANGELISTA, Karine Cavalcanti Maurício Sena; PEDROSA, Lucia Fatima Campos; PAIVA, Maria Sanali Moura Oliveira; DIAS, Paula Cristina Silveira; FERREIRA, Diana Quitéria Cabral; COZZOLINO, Sílvia Maria Franciscato; FAULIN, Tanize Espírito Santo; ABDALLA, Dulcinéia Saes Parra. The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study. Plos One, [S.l.], v. 10, n. 3, p. 1-14, 18 mar. 2015. DOI: 10.1371/journal.pone.0119830. Disponível em: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119830. Acesso em: 26 jul. 2024.pt_BR
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0119830
dc.identifier.urihttps://repositorio.ufrn.br/handle/123456789/59890
dc.languageenpt_BR
dc.publisherPlos Onept_BR
dc.rightsAttribution 3.0 Brazil*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/br/*
dc.subjectRosuvastatin therapypt_BR
dc.subjectZinc and selenium supplementationpt_BR
dc.subjectCoronary artery diseasept_BR
dc.subjectLipid profilept_BR
dc.subjectAntioxidant enzymespt_BR
dc.titleThe hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled studypt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
HypolipidemicPleiotropic_Evangelista_2015.pdf
Tamanho:
459.7 KB
Formato:
Adobe Portable Document Format
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.45 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar